ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1539

High Retention Rate and Sustained Responses with Secukinumab 150mg in Patients with Active Ankylosing Spondylitis: 3-Year Results from a Phase 3 Study

Alan J. Kivitz1, Helena Marzo-Ortega2, Clarence Legerton3, Joachim Sieper4, Ricardo Blanco5, Martin Cohen6, Evie Maria Delicha7, Susanne Rohrer7 and Hanno Richards7, 1Altoona Center for Clinical Research, Duncansville, PA, 2NIHR LBRC, LTHT and LIRMM, UoL, Leeds, United Kingdom, 3Low Country Rheumatology, Articularis Healthcare, Charleston, SC, 4University Clinic Benjamin Franklin, Berlin, Germany, 5Hospital Universitario Marqués de Valdecilla, Santander, Spain, 6McGill University, Montreal, QC, Canada, 7Novartis Pharma AG, Basel, Switzerland

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Ankylosing spondylitis (AS), Biologic agents, interleukins (IL) and tumor necrosis factor (TNF)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Secukinumab provided sustained improvement in the signs and symptoms of ankylosing spondylitis (AS) over 2 years in the MEASURE 2 study (NCT01649375).1,2 Here we report the efficacy and safety of secukinumab over 3 years from the study.

 

Methods: 219 patients (pts) with active AS were randomized to subcutaneous secukinumab 150 mg (72 pts), 75 mg (73 pts) or placebo (PBO, 74 pts) at baseline. At Week (Wk) 16, PBO treated pts were re-randomized 1:1 to secukinumab 150 or 75 mg, irrespective of clinical response. Pts initially randomized to secukinumab and those who switched from PBO to secukinumab at Wk 16 were included in the analysis (secukinumab 150 mg, N = 106 and secukinumab 75 mg, N = 105). Outcome measures at Wk 156 included ASAS20 and 40, ASDAS-CRP inactive disease, ASAS5/6, BASDAI, SF-36 PCS and ASAS partial remission. Analyses stratified by anti-TNFα status (anti–TNFα-naïve and anti-TNFα inadequate response [IR]) were pre-specified. Data are reported as observed. Safety analyses included all pts who received ≥1 dose of secukinumab.

 

Results: At Wk 156, the completion rate for secukinumab 150 mg was 81.1% (86/106), compared to 72.4% (76/105) for 75 mg. The higher discontinuation rate for 75 mg was in part due to lack of efficacy or patient/guardian decision. Efficacy observed across endpoints from Wks 52 to 156 is summarized in the Table. Higher responses were observed in the 150 mg group. Improvements in ASAS20 and ASAS40 responses were sustained in anti–TNFα-naïve and anti–TNFα-IR pts (Table). Over the entire study period, the mean exposure [± SD] to secukinumab was 914.3 ± 315.5 days. The safety and tolerability profile of secukinumab was consistent with previous reports; nasopharyngitis, upper respiratory tract infection, diarrhoea and bronchitis were the most frequently reported adverse events (AEs). The exposure-adjusted incidence rates with secukinumab for AEs of interest were serious infections/infestations (1.5), Crohn’s disease (0.6), malignant/unspecified tumours (0.6) and major adverse cardiovascular events (0.6) per 100 pt-years.

 

Conclusion: Secukinumab 150 mg provided sustained response in the signs and symptoms along with physical function through 3 years in pts with AS, with over 80% retention rate. The safety profile remained favourable and was consistent with previous reports.1,2

 

Reference: 1. Baeten et al. N Engl J Med 2015;373:2534‒48; 2. Marzo-Ortega H, et al. Arthritis Care Res (Hoboken) 2017;doi: 10.1002/acr.23233

                                   

 


Disclosure: A. J. Kivitz, AbbVie, Pfizer, Genentech, UCB, Sanofi/Regeneron and Celgene, 5,Celgene, Pfizer, Sanofi/Regeneron and Genentech, 8; H. Marzo-Ortega, Janssen and Pfizer, 2,Abbvie, Celgene, Janssen, Novartis and UCB,, 5,Abbvie, Celgene, Janssen and UCB, 8; C. Legerton, AbbVie, Ablynx, Acerta, Amgen, AstraZeneca, Celgene, GSK, Janssen, E. Lilly, BMS, Pfizer, Novartis, Sandoz, UCB, Daiichi Sankyo, ChemoCentryx, Boehringer Ingelheim, 2,Novartis, Celgene and Amgen, 8; J. Sieper, AbbVie, Pfizer and Merck, 2,AbbVie, Pfizer, Merck, UCB and Novartis, 5,AbbVie, Pfizer, Merck and UCB, 8; R. Blanco, AbbVie, MSD, and Roche;, 2,AbbVie, Pfizer, Roche, Bristol-Myers, Janssen, and MSD, 5,AbbVie, Pfizer, Roche, Bristol-Myers, Janssen, and MSD, 8; M. Cohen, Abbvie, Amgen, BMS, Celgene, Hospira, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi and UCB, 5,Abbvie, Amgen, BMS, Celgene, Hospira, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi and UCB, 8; E. M. Delicha, Norartis Pharma AG, 3; S. Rohrer, Novartis Pharma AG, 1,Novartis Pharma AG, 3; H. Richards, Novartis Pharma AG, 1,Novartis Pharma AG, 3.

To cite this abstract in AMA style:

Kivitz AJ, Marzo-Ortega H, Legerton C, Sieper J, Blanco R, Cohen M, Delicha EM, Rohrer S, Richards H. High Retention Rate and Sustained Responses with Secukinumab 150mg in Patients with Active Ankylosing Spondylitis: 3-Year Results from a Phase 3 Study [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/high-retention-rate-and-sustained-responses-with-secukinumab-150mg-in-patients-with-active-ankylosing-spondylitis-3-year-results-from-a-phase-3-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/high-retention-rate-and-sustained-responses-with-secukinumab-150mg-in-patients-with-active-ankylosing-spondylitis-3-year-results-from-a-phase-3-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology